KR20230090440A - Cladophora sakaii abott extract with physiological activity and its manufacturing method - Google Patents

Abstract

The present invention relates to a Cladophora sakaii extract having physiological activity and a method for manufacturing the same. The Cladophora sakaii extract with physiological activity which contains naturally collected Cladophora sakaii as an active ingredient is constituted, wherein the Cladophora sakaii extract consists of extraction with an extraction solvent selected from 70 % ethanol or hot water. In addition, since the Cladophora sakaii extract is formulated to have anti-inflammatory, antibacterial, and anti-obesity effects, it is characterized by being able to overcome the side effects and drug resistance problems of chemotherapy drugs such as anti-inflammatory drugs (NSAIDs) used to treat various inflammatory diseases.

Description

Sakai stem end extract having physiological activity and its manufacturing method

The present invention relates to an extract of Sakai cannabis end having physiological activity and a method for producing the same, and more particularly, by providing an extract containing active ingredients having physiological activity beneficial to the human body from Sakai cannabis end collected from nature. It relates to an extract that overcomes various problems caused by the use of conventional chemotherapeutic agents and a method for preparing the same.

In general, inflammation is an in vivo immune response to damage or infection of a specific tissue, and immune cells act to maximally suppress such tissue damage.

Macrophage, a type of immune cell, produces inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6. produce and secrete

In addition, lipopolysaccharide (LPS), one of the inflammatory receptors that stimulate macrophages to release cytokines, activates inflammatory response factors to induce inducible nitric oxide synthase (iNOS) and cyclooxygenase -2 (cyclooxygenase-2: COX-2) is expressed, and inflammatory mediators, nitric oxide (NO) and prostaglandin E2 (Prostaglandin E2: PGE2) are produced to promote the inflammatory response.

In particular, iNOS is known to be deeply involved in anti-inflammatory and antibacterial activities, such as producing high concentrations of NO and causing nitrification and oxidation reactions.

However, when these inflammatory cytokines and inflammatory mediators are excessively produced in the human body, necrosis of normal cells and tissues is deepened due to the enhancement of the inflammatory response, and chronic inflammatory diseases such as sepsis, damage to nerve tissue, and autoimmune diseases are caused. Causes harmful effects to living organisms.

Conventionally, steroids and non-steroidal anti-inflammatory drugs (NSAIDs) are mainly used as treatments for various inflammatory diseases.

Referring to the prior art, the composition and action of anti-inflammatory drugs are schematically reviewed. Korean Patent Publication No. 10 - 2002 - 0086945 discloses paracetamol or a non-steroidal anti-inflammatory drug (NSAID), or a pharmaceutically acceptable salt or solvate thereof, And a combination comprising another drug and, if necessary, one or more pharmaceutically acceptable carriers, wherein the other drug comprises a non-steroidal anti-inflammatory agent consisting of mirtazapine or a pharmaceutically acceptable salt or solvate thereof. A pharmaceutical combination is provided.

As another example, Korean Patent Publication No. 10 - 2016 - 0046138 discloses aspirin, naproxen, ibuprofen, aceclofenac, meloxicam, dexibuprofen, cetaminophen, diflunisal, salsalate, sodium salicylate, cinnoxi Cam, piroxicam, tenoxicam, diclofenac, etodolac, kenorolac, sulindac, fenbufen, flurbiprofen, ketoprofen, triaprofenic acid, fenoprofen, oxaprozin, flufenamic acid Disclosed is a pharmaceutical composition for preventing or treating infectious diseases caused by pathogenic microorganisms containing a nonsteroidal anti-inflammatory agent selected from the group consisting of mefenamic acid, meclofenamate, tolfenamic acid, etofenamate and indomethacin.

On the other hand, in another prior art, a technique related to preparations having activity such as anti-inflammation using natural substances as raw materials is known. For example, Korean Patent No. 10 - 0530274 relates to an extract of triticale and a composition containing the same, It inhibits the activation of inflammatory factors expressed by various stimuli and inhibits enzymes that mediate anti-inflammatory mechanisms, thereby reducing pain (acute pain, chronic pain, inflammatory pain, neuropathic pain, postoperative pain, migraine, arthralgia) and inflammatory diseases. An effective and safe composition for the prevention and treatment of is disclosed.

Korean Patent Publication No. 10 - 2002 - 0086945 (2002.11.20) Korean Patent Publication No. 10 - 2016 - 0046138 (2016.04.28) Korean Registered Patent No. 10 - 0530274 (2005.11.22) Korean Registered Patent No. 10 - 0878331 (2009.01.14)

As described above, in the prior art, steroids and non-steroidal anti-inflammatory drugs (NSAIDs) are basically used to treat and improve various inflammatory diseases.

However, on the other side of anti-inflammatory effects, these chemotherapeutic agents may cause serious side effects in various cardiovascular or digestive systems.

In particular, as the problem of drug resistance is seriously raised due to the widespread use of anti-inflammatory drugs, the need for alternative treatments is emerging.

Therefore, the present invention is intended to overcome various side effects and drug resistance problems of existing chemotherapeutic agents by preparing an extract containing an active ingredient having physiological activity for anti-inflammatory, antibacterial, and anti-obesity.

Accordingly, the present invention was invented to solve the problems of the prior art as described above,

It constitutes an extract of Sakai candied end which has a physiological activity containing Sakai candied end collected from nature as an active ingredient.

The Sakai stem end extract consists of extracting with an extraction solvent selected from 70% ethanol or hot water.

The Sakai hemp end extract is configured to act as an anti-inflammatory, antibacterial, and anti-obesity.

In addition, as a method for producing an extract of Sakai stem end having physiological activity, the raw material of Sakai stand end end collected from the sea is washed, lyophilized, and pulverized to obtain Sakai end end powder;

Shaking extraction by adding 70% ethanol to the Sakai hemp end powder, and filtering the supernatant except for the residue through centrifugation with a filter to obtain a primary Sakai hemp end end extract;

Adding 70% ethanol to the Sakai hemp end residue, shaking extraction again, and centrifuging and filtering to obtain a secondary Sakai hemp end end extract as a supernatant;

Mixing the primary Sakai hemp end extract and the secondary Sakai hemp end end extract and vacuum concentrating to 70% by weight of the mixture;

Freezing the concentrated Sakai cannabis end end extract to obtain a Sakai end end extract having physiological activity.

In addition, as a method for producing an extract of Sakai stem end having physiological activity, the raw material of Sakai stand end end collected from the sea is washed, lyophilized, and pulverized to obtain Sakai end end powder;

Adding tertiary distilled water to the Sakai stem end powder and heating at 90 to 100 ° C to obtain a first Sakai end end extract;

After cooling the primary Sakai hemp end end extract at room temperature, obtaining a secondary Sakai end end extract by filtering the supernatant except for the residue through centrifugation with a filter;

Mixing the first and second Sakai hemp end extracts and vacuum-concentrating them to 50% by weight;

By comprising the step of freeze-drying the concentrated Sakai hemp end end extract to obtain a Sakai end end extract having physiological activity,

It is possible to achieve the purpose of overcoming the side effects and drug resistance problems of chemotherapeutic agents such as anti-inflammatory drugs (NSAIDs) previously used for the treatment of various inflammatory diseases.

The present invention provides an extract containing an active ingredient having a beneficial physiological activity to the human body from the end of Sakai cannabis collected from nature.

In particular, the present invention is anti-inflammatory, antibacterial, antibacterial, antibacterial, antibacterial, It has the effect of providing an extract having physiological activity in actions such as anti-obesity.

In addition, the present invention minimizes various side effects of conventional chemotherapeutic agents, such as various cardiovascular or digestive disorders, and as a natural agent, it is possible to relieve inflammatory symptoms as well as improve obesity without fear of drug resistance. There is an advantage.

Figure 1 is a graph of anti-inflammatory activity test results by immune cell proliferation and toxicity analysis of Sakai cannabis mal extract having physiological activity according to the present invention.
Figure 2 is a graph of anti-inflammatory activity test results by analyzing the NO production inhibitory ability of the Sakai cannabis end extract having physiological activity according to the present invention.
Figure 3 is a graph of anti-inflammatory activity test results by gene expression analysis of the sakai hemp end extract having physiological activity according to the present invention.
Figure 4 is an image of the antibacterial activity test result of the sakai hemp end extract having physiological activity according to the present invention.
5 and 6 are graphs of anti-obesity activity test results of Sakai cannabis mal extract having physiological activity according to the present invention.
Figure 7 is a flow chart showing a first method for extracting Sakai cannabis end extract having physiological activity according to the present invention.
8 is a flow chart showing a second method for extracting Sakai cannabis end extract having physiological activity according to the present invention.

Hereinafter, the configuration and action according to a preferred embodiment of the sakai stem end extract having physiological activity and the manufacturing method of the present invention will be described in detail with reference to the accompanying drawings. In the following description, detailed descriptions of parts that can be easily implemented by those skilled in the art may be omitted.

In addition, since the following description describes the present invention with respect to preferred embodiments, the present invention is not limited by the following examples, and it is natural that various modifications may be provided without departing from the scope of the present invention. will be.

It should be noted that the Sakai cannabis end extract having physiological activity to which the technology of the present invention is applied and the manufacturing method thereof relate to an extract containing an active ingredient having a physiological activity beneficial to the human body from Sakai cannabis end collected from nature.

'Cladophora sakaii Abbott' is a marine plant belonging to the order of the green algae sakaii, and is mainly distributed in the west coast of the North Pacific Ocean. am.

Sakai hemp ends form dark green plants and form branches in the form of bundles of threads. It grows to a height of about 5 to 22 cm by attaching roots to bedrock, and growth is achieved by cell division in the middle and upper parts.

The Sakai hemp end extract having physiological activity of the present invention is a dry powder obtained by extracting active ingredients from natural Sakai hemp end using an extraction solvent and concentrating the extract, and is configured to have physiological activity against inflammation, antibacterial, and anti-obesity.

The Sakai stem end extract of the present invention is formed by extraction with an extraction solvent selected from 70% ethanol or hot water. Hereinafter, the method for preparing the Sakai end end extract to which the technology of the present invention is applied is as follows.

[Extraction method using ethanol extraction]

The steps for extracting the Sakai stem end extract having physiological activity using 70% ethanol extraction solvent are as follows.

(a) In the step of obtaining the powder of the end of Sakai end, the raw material of the end of the end of Sakai end collected from the sea is washed, lyophilized, and pulverized to obtain the end of Sakai end end powder (S10).

(b) in the step of obtaining the primary Sakai cannabis end extract, shaking extraction was performed by adding 70% ethanol to the Sakai cannabis end powder, and the supernatant excluding the residue was filtered through a filter through centrifugation to obtain the first Sakai cannabis end powder A horse extract is obtained (S20).

(c) in the step of obtaining the secondary Sakai cannabis end extract, 70% ethanol was added to the Sakai cannabis end end residue, shaken extraction was performed again, and the supernatant was centrifuged and filtered to obtain a secondary Sakai end end extract (S30).

(d) In the step of vacuum concentration, the primary Sakai stem end extract and the secondary Sakai stem end end extract are mixed and vacuum concentrated to 70% by weight of the mixture (S40).

(E) In the step of obtaining the Sakai end end extract, the concentrated Sakai end end end extract is freeze-dried to obtain the final Sakai stand end end extract (S50).

[Extraction method using hot water extraction]

The preferred and verified steps of the present invention for the method suitable for extracting the extract of Sakae hemp stem using a hot water extraction solvent are as follows.

(a) In the step of obtaining the powder of the end of Sakai end, the raw material of the end of the end of Sakai end collected from the sea is washed, lyophilized, and pulverized to obtain the end of Sakai end end powder (S110).

(b) In the step of obtaining the primary Sakai stem end end extract, tertiary distilled water is added to the Sakai end end end powder and heated at 90 to 100 ° C to obtain the first Sakai end end end extract (S120).

(c) in the step of obtaining the secondary Sakai stem end extract, the first Sakai stem end end extract is cooled at room temperature, and then the supernatant excluding the residue is filtered through a filter to obtain a secondary Sakai end end extract (S130).

(d) In the vacuum concentration step, the first and second Sakai hemp end extracts are combined and vacuum concentrated to 50% by weight.

(E) In the step of obtaining the Sakai stem end end extract, the concentrated Sakai end end end extract is freeze-dried to obtain the final Sakai stand end end extract (S140).

Hereinafter, an embodiment including the present invention will be configured to more closely grasp the effects thereof.

<Example 1 - Preparation of raw materials for Sakai hemp ends>

The raw material of Cladophora sakaii Abott 1972 collected from Bangseok-ri, Pohang, Gyeongsangbuk-do was thoroughly washed with tap water, and then lyophilized and pulverized to obtain a powder.

<Example 2 - Preparation of 70% ethanol extraction solvent Sakai cannabis end extract>

The addition of 250 ml of 70% ethanol as an extraction solvent to 25 g of Sakai stem end raw material powder was repeated twice (500 ml in total), followed by first extraction by shaking at 25 ° C, and then centrifugation and paper filter to obtain the supernatant.

Secondary extraction was performed under the same conditions by adding 250 ml of 70% ethanol to the residue again.

The primary Sakai cannabis end end extract and the secondary Sakai end end end extract were mixed (about 800 ml), concentrated to 70% or more with a vacuum concentrator, and lyophilized to recover Sakai end end end extract powder in ethanol solvent.

<Example 3 - Preparation of Sakai hemp end extract with hot water extraction solvent>

40 g of Sakai hemp end raw material powder was put into an Erlenmeyer flask, 2000 ml of hot water was added as an extraction solvent, and then heated at about 90 to 100 ° C. for 30 minutes.

After cooling to room temperature, the residue was removed through centrifugation and a paper filter to obtain a supernatant. After concentrating the supernatant to 50% or more with a vacuum concentrator, it was lyophilized to recover the hot-water solvent extract powder of Sakai Daedan end.

<Example 4.1 - Anti-inflammatory activity test by immune cell proliferation and toxicity assay>

Immune cell proliferation and toxicity analysis experiments were performed using the ethanol solvent Sakai canadian end extract powder and the hot water solvent Sakai canadian end extract powder obtained in Examples 2 and 3 above.

RAW 264.7 cells, which are mouse-derived immune cells, were cultured and seeded at 1x10 ⁶ cell/mL in a 96-well cell culture plate.

Cells were cultured for 24 hours at 37°C and 5% CO ₂ conditions.

Thereafter, the cells were activated by treatment with LPS at a concentration of 1 ug/ml, and the LPS-induced RAW 264.7 cells were treated with 10 ug/ml, 50 ug/ml, and 100 ug/ml of Sakai stem end extract.

After reacting for 5 hours, the supernatant was removed, the cells were treated with ez-cytox (DoGen Co., Ltd.), and the absorbance was measured at 450 nm after reacting for 1 hour.

Anti-inflammatory activity test results by immune cell proliferation and toxicity analysis are shown in the graph of FIG. 1 below. It can be seen that both the 70% ethanol extract and the hot water extract of Sakai cannabis end show no toxicity to RAW 264.7 cells.

<Example 4.2 - Anti-inflammatory activity test by anti-inflammatory effect analysis (ability to inhibit nitric oxide production)>

Experiments were conducted to confirm the ability to inhibit nitric oxide production using the ethanol solvent Sakai cannabis end extract powder and the hot water solvent Sakai cannabis end extract powder obtained in Examples 2 and 3.

RAW 264.7 cells, which are mouse-derived immune cells, were cultured and seeded in a 96-well cell culture plate at 1x10 ⁶ cell/mL.

Cells were cultured for 24 hours at 37°C and 5% CO ₂ conditions.

Thereafter, the cells were activated by treatment with LPS at a concentration of 1 ug/ml, and the LPS-induced RAW 264.7 cells were treated with 10 ug/ml, 50 ug/ml, and 100 ug/ml of Sakai stem end extract.

After reacting for 5 hours, transfer the supernatant to another plate by 100ul,

100 ul each of Griess reagent was treated, and after 30 minutes, absorbance was measured at a wavelength of 540 nm.

The concentration of NO was calculated by comparison with a standard straight line obtained using sodium nitrite (NaNO ₂ , Sigma-Aldrich).

The anti-inflammatory activity test results by analysis of nitric oxide production inhibitory ability are shown in the graph of FIG. 2 below. It can be confirmed that NO production was suppressed in the 70% ethanol extract of Sakai hemp.

<Example 4.3 - Anti-inflammatory activity test by anti-inflammatory effect analysis (gene expression analysis)>

Reverse transcription PCR (RT-PCR) experiments were performed using the ethanol solvent Sakai canadian end extract powder and the hot water solvent Sakai canadian end extract powder obtained in Examples 2 and 3.

In the same manner as in Example 4.2, LPS-induce RAW 264.7 cells were treated with 10ug/ml, 50ug/ml, and 100ug/ml of Sakai stem end extract.

After 5 hours of reaction, the supernatant was removed and RNA was isolated from the cells using Trizol reagent. After synthesizing the RNA into cDNA, the cDNA is amplified with the primers of TNF-α, IL-6, iNOS, and β-actin shown in Table 1 below.

Gene Sequences TNF-α Forward AGGTTCTGTCCCTTTCACTCACTG Reverse AGAAGACCTGGGAGTCAAGGTA IL-6 Forward TTCCTCTCTGCAAGAGACT Reverse TGTATCTCTCTGAAGGACT iNOS Forward CTGCAGCACTTGGATCAGGAACCTG Reverse GGGAGTAGC CTGTGTGCACCTGGAA β-actin Forward ATGTGCAAAAAGCTGGCTTTG Reverse ATTTGTGGTGGATGATGGAGG

Each amplified fragment was loaded on an agar gel and the intensity of the expressed band was confirmed through electrophoresis.

The anti-inflammatory activity test results by gene expression analysis are shown in the graph of FIG. 3 below.

It can be seen that as the concentration of 70% ethanol extract of Sakai hemp stem increased, iNOS, which produces inflammatory cytokines TNF-α and IL-6 and inflammatory mediator NO, was reduced compared to the control group β-actin.

As described above, the Sakai hemp extract of the present invention through Examples 4.1 to 4.3 inhibits the expression of LPS, which releases cytokines such as TNF-α and IL-6, and the iNOS gene, an inflammatory substance induced by LPS. It was confirmed that it was effective in suppressing the production of NO, an inflammatory mediator, by effectively controlling it.

<Example 5 - Antibacterial activity test>

A Sakai hemp end extract sample was prepared by dissolving it in dimethyl sulfoxide (DMSO) at a concentration of 20 mg/ml (0.6 mg/30 ul). 8 pathogens (4 gram-negative: E. coli, K. pneumoniae, V. parahaemolyticus, P. aerosinosa, 4 gram-positive: S. aureus, L. monocytogens, B. cereus, S. typhi) in LB medium 37 After culturing overnight at ℃, spread 300ul in a 6X6 square dish.

30ul of each sample was dropped on an 8mm paper disk.

When the sample is sufficiently absorbed, transfer it to a square dish with sterilized tweezers. Clear zone was observed after overnight at 37°C.

The antibacterial activity test results are shown in FIG. 4 below. Antibacterial activity against B. cereus was observed in 70% ethanol extract of Sakai hemp end. (Red box, paper disk, diameter 11 mm)

<Example 6 - Anti-obesity activity test>

When 3T3-L1 fibroblasts occupy 70-80% of the culture flask area, the medium is washed with phosphate buffered saline (PBS).

After treatment with 0.05% trypsin-EDTA (trypsin-EDTA) to detach the cells, the medium is neutralized.

After collecting the cells in a test tube and centrifuging at 1,000 rpm for 3 minutes, the supernatant is removed and fresh medium is added to release the cells. After measuring the number of cells, the cells are dispensed in a 6-well plate to form 5 X 105 cells per well. When the cells are attached, the medium is changed and cultured until full.

It is cultured for another 2 days by replacing with 10% FBS/DMEM differentiation medium containing methylisobutylxanthine, insulin, and dexamethasone. The medium was replaced with 10% FBS/DMEM medium containing 1 ug/ml insulin and further cultured for 2 days.

After the replacement with the insulin-containing medium, intracellular fat globules can be observed.

The medium is replaced with 10% FBS/DMEM medium and cultured for 2 more days. This process is repeated once more, and fully differentiated adipocytes can be observed after 2-3 days.

When differentiation is complete, the medium in the well is discarded, 1ml of 10% formalin is added, and left for 5 minutes. After discarding the 10% formalin, 1ml of 10% formalin was added to each well and fixed for 1 hour.

Discard the 10% formalin contained in each well, add 2 ml of 60% isopropyl alcohol, wash, discard and dry.

Prepared oil-red O working solution (ORO stock: 0.7g oil red O + 200ml isopropyl alcohol, stored at 4℃, ORO working solution: ORO stock and water After mixing at a ratio of 6:4, leave at room temperature for 20 minutes, then filter using a syringe filter (0.2um)) into each well by 1ml and leave for 10 minutes. Discard the ORO working solution and wash with water 4 times.

Observe under a microscope in the presence of water and take pictures.

Discard the water and dry. The stained cells are photographed in a plate state.

Add 1ml of 100% isopropyl alcohol to elute the dyed ORO. Divide 300 μl into a 96-well plate and measure absorbance at 510 nm.

Anti-obesity activity test results are shown in Figures 5 and 6 below.

It can be confirmed that the anti-obesity effect was shown by the differentiation of adipocytes at a level of 77% compared to the mature cells in the hot water extract of Sakai Daemary end.

As described above, the Sakai cannabis end extract having physiological activity according to the present invention and the manufacturing method thereof provide an extract containing an active ingredient having a beneficial physiological activity to the human body from Sakai cannabis end collected from nature.

In particular, the present invention is anti-inflammatory, antibacterial, antibacterial, antibacterial, antibacterial, It has the effect of providing an extract having physiological activity in actions such as anti-obesity.

In addition, the sakai stem end extract having physiological activity of the present invention minimizes side effects such as various cardiovascular and digestive disorders of conventional chemotherapeutic agents, and as a natural agent, there is no concern about drug resistance, as well as alleviation of inflammatory symptoms as well as obesity There is an advantage that can promote improvement effect.

Therefore, it is expected that the use of the sakai stem end extract having physiological activity according to the present invention can be used in pharmaceuticals, quasi-drugs, health functional foods, etc. for the prevention, improvement, or treatment of various inflammatory diseases.

Not applicable.

Claims (5)

Sakai candied end extract having physiological activity containing Sakai candied end as an active ingredient. According to claim 1,
The Sakai end end extract is Sakai end end extract having physiological activity, characterized in that extracted with an extraction solvent selected from 70% ethanol or hot water. According to claim 1,
The Sakai stem end extract is an extract having physiological activity, characterized in that it has anti-inflammatory, antibacterial, and anti-obesity action. Washing the raw material collected from the sea, freeze-drying, and pulverizing to obtain Sakai cannabis end powder;
Shaking extraction by adding 70% ethanol to the Sakai hemp end powder, and filtering the supernatant except for the residue through centrifugation with a filter to obtain a primary Sakai hemp end end extract;
Adding 70% ethanol to the Sakai hemp end residue, shaking extraction again, and centrifuging and filtering to obtain a secondary Sakai hemp end end extract as a supernatant;
Mixing the primary Sakai hemp end extract and the secondary Sakai hemp end end extract and vacuum concentrating to 70% by weight of the mixture;
A method for producing a Sakai candied end extract having physiological activity, comprising the step of obtaining a Sakai candied end end extract having physiological activity by freeze-drying the concentrated Sakai candied end end extract. Washing the raw material collected from the sea, freeze-drying, and pulverizing to obtain Sakai cannabis end powder;
Adding tertiary distilled water to the Sakai stem end powder and heating at 90 to 100 ° C to obtain a first Sakai end end extract;
After cooling the primary Sakai hemp end end extract at room temperature, obtaining a secondary Sakai end end extract by filtering the supernatant except for the residue through centrifugation with a filter;
Vacuum-concentrating the secondary Sakai hemp end extract to 50% by weight;
A method for producing a Sakai stem end extract having physiological activity, comprising the step of obtaining a Sakai end end end extract having physiological activity by combining the first and secondly concentrated Sakai end end end extracts and freeze-drying.

Images